Literature DB >> 19557866

Apolipoprotein E-dependent accumulation of Alzheimer disease-related lesions begins in middle age.

Eloise Kok1, Satu Haikonen, Teemu Luoto, Heini Huhtala, Sirkka Goebeler, Hannu Haapasalo, Pekka J Karhunen.   

Abstract

OBJECTIVE: To study the prevalence and age dependency of senile plaques (SP) and neurofibrillary tangles (NFT), the brain changes characteristic of Alzheimer disease (AD), and their association with apolipoprotein E (APOE) genotypes in a community-dwelling normal population.
METHODS: This neuropathological study used both silver staining and A beta immunohistochemistry in brain tissue microarrays, including SP coverage and NFT counts from frontal cortex and hippocampus, and APOE genotyping, and was performed on a consecutive prospective series of 603 subjects (aged between 0 and 97 years) of an unselected population living outside of institutions. Cases were subjected to autopsy following sudden or unexpected out-of-hospital death, covering 22.1% of the mortality of Tampere, Finland and its surroundings. None died of AD, although 22 (3.7%) were demented and 10 (1.7%) had memory problems.
RESULTS: Of the series, 30.8% had SP, and 42.1% had NFT; these occurred more commonly among females and showed a strong relationship with age. Both changes had already appeared at around 30 years of age, reaching an occurrence of almost 100% in the oldest. SP were more frequent in APOE epsilon 4-carriers compared with noncarriers in every age group except the oldest (>90 years). The difference was most evident during the ages 50 to 59 years, where 40.7% of epsilon 4-carriers had SP, compared with 8.2% in noncarriers (odds ratio, 8.39; 95% confidence interval, 2.55-27.62). The difference in NFT prevalence between APOE genotypes was not statistically significant in any age group.
INTERPRETATION: The brain changes associated with AD may already begin developing early in middle age, especially among APOE epsilon 4 carriers.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19557866     DOI: 10.1002/ana.21696

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  132 in total

1.  Gray matter network associated with risk for Alzheimer's disease in young to middle-aged adults.

Authors:  Gene E Alexander; Kaitlin L Bergfield; Kewei Chen; Eric M Reiman; Krista D Hanson; Lan Lin; Daniel Bandy; Richard J Caselli; James R Moeller
Journal:  Neurobiol Aging       Date:  2012-03-08       Impact factor: 4.673

Review 2.  Mild cognitive impairment: pathology and mechanisms.

Authors:  Elliott J Mufson; Lester Binder; Scott E Counts; Steven T DeKosky; Leyla de Toledo-Morrell; Stephen D Ginsberg; Milos D Ikonomovic; Sylvia E Perez; Stephen W Scheff
Journal:  Acta Neuropathol       Date:  2011-11-19       Impact factor: 17.088

3.  Midlife memory improvement predicts preservation of hippocampal volume in old age.

Authors:  Paul R Borghesani; Kurt E Weaver; Elizabeth H Aylward; Anne L Richards; Tara M Madhyastha; Ali R Kahn; Olivia Liang; Rachel L Ellenbogen; M Faisal Beg; K Warner Schaie; Sherry L Willis
Journal:  Neurobiol Aging       Date:  2010-11-12       Impact factor: 4.673

4.  Multiple Effect of APOE Genotype on Clinical and Neuroimaging Biomarkers Across Alzheimer's Disease Spectrum.

Authors:  Ying Liu; Lan Tan; Hui-Fu Wang; Yong Liu; Xiao-Ke Hao; Chen-Chen Tan; Teng Jiang; Bing Liu; Dao-Qiang Zhang; Jin-Tai Yu
Journal:  Mol Neurobiol       Date:  2015-08-23       Impact factor: 5.590

5.  Association of lifetime cognitive engagement and low β-amyloid deposition.

Authors:  Susan M Landau; Shawn M Marks; Elizabeth C Mormino; Gil D Rabinovici; Hwamee Oh; James P O'Neil; Robert S Wilson; William J Jagust
Journal:  Arch Neurol       Date:  2012-05

6.  ApoE4 Accelerates Early Seeding of Amyloid Pathology.

Authors:  Chia-Chen Liu; Na Zhao; Yuan Fu; Na Wang; Cynthia Linares; Chih-Wei Tsai; Guojun Bu
Journal:  Neuron       Date:  2017-12-06       Impact factor: 17.173

7.  Periodontal disease associates with higher brain amyloid load in normal elderly.

Authors:  Angela R Kamer; Elizabeth Pirraglia; Wai Tsui; Henry Rusinek; Shankar Vallabhajosula; Lisa Mosconi; Li Yi; Pauline McHugh; Ronald G Craig; Spencer Svetcov; Ross Linker; Chen Shi; Lidia Glodzik; Schantel Williams; Patricia Corby; Deepak Saxena; Mony J de Leon
Journal:  Neurobiol Aging       Date:  2014-11-05       Impact factor: 4.673

Review 8.  ApoE and Aβ in Alzheimer's disease: accidental encounters or partners?

Authors:  Takahisa Kanekiyo; Huaxi Xu; Guojun Bu
Journal:  Neuron       Date:  2014-02-19       Impact factor: 17.173

9.  Linear Combinations of Multiple Outcome Measures to Improve the Power of Efficacy Analysis ---Application to Clinical Trials on Early Stage Alzheimer Disease.

Authors:  Chengjie Xiong; Jingqin Luo; John C Morris; Randall Bateman
Journal:  Biostat Epidemiol       Date:  2017-06-02

Review 10.  Immunotherapeutic approaches for Alzheimer's disease in transgenic mouse models.

Authors:  Thomas Wisniewski; Allal Boutajangout
Journal:  Brain Struct Funct       Date:  2009-12-10       Impact factor: 3.270

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.